Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 14, 2025

Top Stock Reports for SAP, Prologis & Bank of New York Mellon

View original at finance.yahoo.com
Top Stock Reports for SAP, Prologis & Bank of New York Mellon Friday, November 14, 2025 The Zacks Research Daily presents the best research output of our analyst team…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Regional risks tied to agriculture and real estate warrant caution for United Security Bancshares

    80% confidence
  • BNY Mellon's global expansion efforts, robust assets under management balance and solid balance sheet will likely aid the top line

    80% confidence
  • SAP's fourth-quarter and 2026 pipeline appear strong, driven by renewed momentum across industries

    80% confidence
  • SAP is riding on healthy Cloud ERP growth and uptake of its Rise with SAP and Grow with SAP solutions amid a volatile macro backdrop

    80% confidence
  • Prologis is well-poised to benefit from its portfolio of strategically located industrial real estate in some of the world's busiest distribution markets

    80% confidence
  • Cloud revenue is expected near the low end of €21.6-€21.9 billion, with non-IFRS operating profit near the high end of €10.3-€10.6 billion

    80% confidence
  • United Security Bancshares exhibits solid fundamentals, with Q3 2025 net interest margin expanding to 4.35%

    80% confidence
  • BNY Mellon's business transformation plan, combined with the buyout of Archer, is expected to boost its market share

    80% confidence
  • Amphenol benefits from a diversified business model that lowers volatility of individual geographies

    80% confidence
  • AI is poised to be a key catalyst in fueling double-digit total revenue growth through 2027 for SAP

    80% confidence
  • Credit concerns persist for United Security Bancshares, notably in student loans, with charge-offs rising to $4.8 million and over 45% in deferment

    80% confidence
  • Customers remain focused on cost controls and delay their decision-making with respect to leasing amid macroeconomic uncertainty and geopolitical issues

    80% confidence
  • Strong licensing momentum in the smartphone business will likely drive InterDigital's top line

    80% confidence
  • Vail Resorts is grappling with declining pass sales, softer visitation patterns, and ineffective marketing execution

    80% confidence
  • Ingersoll Rand's operational efficiencies are being dampened by a rise in cost of sales due to high cost of raw materials

    80% confidence
  • Prologis is converting some of its warehouses into data centers to capitalize on the growing opportunity in this asset category

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com